No Data
No Data
Wohua Pharmaceutical (002107.SZ): Net profit of 9.6672 million yuan in the first quarter decreased by 62.01% year-on-year
Gelonghui, April 26 | Wohua Pharmaceutical (002107.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 215 million yuan, down 8.49% year on year; net profit attributable to shareholders of listed companies was 9.6672 million yuan, down 62.01% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 8.225,800 yuan, down 66.80% year on year; basic earnings per share were 0.02 yuan.
Wohua Pharmaceutical (002107.SZ) received the “Advance Notice of Administrative Penalty”
Wohua Pharmaceutical (002107.SZ) issued an announcement. Recently, the company received the “Advance Notice of Administrative Penalty” (penalty word [Wohua Pharmaceutical (002107.SZ) received the “Advance Notice of Administrative Punishment”] No. 3) issued by the Shandong Regulatory Bureau of the China Securities Regulatory Commission. The relevant details are now announced as follows.
Wohua Pharmaceutical (002107.SZ): Net profit for 2023 fell 45.27% to 587.671 million yuan, and plans to pay 10 2.5 yuan
Gelonghui, March 29 | Wohua Pharmaceutical (002107.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 909.5 million yuan, a year-on-year decrease of 10.38%; net profit attributable to shareholders of listed companies was 587.671 million yuan, a year-on-year decrease of 45.27%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 568.975 million yuan, a year-on-year decrease of 45.69%; basic income per share is 0.10 yuan; plans to distribute a cash dividend of 2.50 yuan (tax included) for every 10 shares to all shareholders.
Wohua Pharmaceutical (002107.SZ): As of January 10, 2024, the number of company owners was 38,953
Gelonghui, March 13 | Wohua Pharmaceutical (002107.SZ) said on the investor interactive platform that as of January 10, 2024, the number of company owners was 38,953.
Wohua Pharmaceutical (002107.SZ) received a warning letter from the Shandong Securities Regulatory Bureau
Wohua Pharmaceutical (002107.SZ) announced that the company recently received the China Securities Regulatory Commission from the Shandong Regulatory Bureau...
Changes in the A-share Chinese medicine sector boosted, and Wohua Pharma hit a rise and stop
Gelonghui, December 11 | Wohua Pharmaceutical hit a rise and fall, Kangyuan Pharmaceutical surged 7%, and Tianshili, Da Rentang, and China Resources 39 followed suit. According to the news, in order to deal with the high incidence of mycoplasma pneumoniae infections, Jin Zhen oral solution developed by Kangyuan Pharmaceutical has become a “traditional Chinese medicine option” for treatment. Eling Pharmaceutical has also initiated clinical trials on the efficacy and safety of Lianhua Qingfeng granules in treating mycoplasma pneumonia in children.
No Data